MHRA Grants HAE Patients Early Access to BioCryst’s Berotralstat in United Kingdom


RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

More:
MHRA Grants HAE Patients Early Access to BioCryst’s Berotralstat in United Kingdom

Related Posts